Did Novavax Just Pass Its Biggest Hurdle?
Novavax (NASDAQ: NVAX) has kept investors on the edge of their seats all year. The company initially was a favorite in the coronavirus vaccine race. It began clinical trials around the same time as today's market leaders Pfizer and Moderna. And it scored a $1.6 billion investment from the U.S. government last year. Yet, Novavax has lagged when it comes to actually bringing a vaccine to market. That's because manufacturing issues have plagued the company.
But Novavax may have just given investors a positive sign. And this sign could mean commercialization is on the way. Let's take a closer look at the news that might bode well for Novavax -- and its share performance.
Image source: Getty Images.
Source Fool.com
